Rationale and Design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial
| العنوان: | Rationale and Design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial |
|---|---|
| المؤلفون: | Amat-Santos IJ, Sánchez-Luna JP, Abu-Assi E, Melendo Viu M, Cruz-Gonzalez I, Nombela-Franco L, Muñoz García AJ, García Blas S, de la Torre Hernandez JM, Romaguera R, Sánchez-Recalde Á, Díez Gil JL, López Otero D, Gheorge L, Ibáñez B, Iñiguez Romo A, Raposeiras-Roubín S |
| المصدر: | EUROPEAN JOURNAL OF HEART FAILURE r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| بيانات النشر: | WILEY-BLACKWELL, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | cardiovascular system, Dapagliflozin, Heart Failure, Sodium-glucose co-transporter 2 inhibitor, Trial Design |
| الوصف: | Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients undergoing TAVI. |
| تدمد: | 1388-9842 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::2a47e53508a5881b115ce3ad255f92a9Test https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15020Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.RECOLECTA.....2a47e53508a5881b115ce3ad255f92a9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13889842 |
|---|